ArticleCureus2025
Predictive Role of CX3CL1 and D-dimer Levels in Mortality Risk Stratification for COPD Patients With COVID-19.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this retrospective study conducted at Yulin Hospital, the First Affiliated Hospital of Xi'an Jiaotong University (Yulin, SN, CHN), we aimed to investigate the predictive role of CX3CL1 and D-dimer for mortality in hospitalized chronic obstructive pulmonary disease (COPD) patients with COVID-19.
methodsComplete blood counts and inflammatory cytokine levels were collected at admission from hospitalized COPD patients with COVID-19 to explore the relationship between inflammatory parameters and mortality of COPD patients with COVID-19.
resultsCompared to severe COPD with COVID-19 patients, circulating biomarkers of CX3CL1 (453.3 vs. 305.3 pg/mL,
conclusionCirculating inflammatory biomarkers of CX3CL1 and D-dimer have shown the potential to predict mortality among COPD patients with severe COVID-19. Monitoring CX3CL1 and D-dimer levels could enhance clinical decision-making and risk stratification, potentially guiding more effective treatment strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.